MIRA Pharmaceuticals, Inc.

DB:K6S Stock Report

Market Cap: €15.8m

MIRA Pharmaceuticals Future Growth

Future criteria checks 0/6

MIRA Pharmaceuticals is forecast to grow earnings and revenue by 14.4% and 86.4% per annum respectively while EPS is expected to grow by 8.3% per annum.

Key information

14.4%

Earnings growth rate

8.3%

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth rate86.4%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:K6S - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026276-9396N/A2
12/31/2025N/A-10-14-83
12/31/2024N/A-8-3-63
6/30/2024N/A-13-5-5N/A
3/31/2024N/A-12-5-5N/A
12/31/2023N/A-12-5-5N/A
9/30/2023N/A-8-4-4N/A
6/30/2023N/A-6-4-4N/A
3/31/2023N/A-7-5-5N/A
12/31/2022N/A-7-6-6N/A
3/31/2022N/A-4-3-3N/A
12/31/2021N/A-2-1-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: K6S is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: K6S is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: K6S is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: K6S is forecast to have no revenue next year.

High Growth Revenue: K6S is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if K6S's Return on Equity is forecast to be high in 3 years time


Discover growth companies